A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

TerminatedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

May 27, 2020

Study Completion Date

May 27, 2020

Conditions
Glomerulosclerosis, Focal SegmentalMinimal Change DiseaseDiabetic Nephropathies
Interventions
OTHER

FSGS/TR-MCD

This is a non-interventional study

OTHER

Diabetic Nephropathy (DN)

This is a non-interventional study

Trial Locations (18)

48066

St. Clair Nephrology, Roseville

64111

Clinical Research Consultants, Kansas City

76015

Arlington Nephrology, PC, Arlington

78207

South Texas Renal Care Group (Downtown), San Antonio

91206

Glendale Adventist Medical Center, Glendale

85210-6041

Aventiv Research - Phoenix, Mesa

92395-8322

DaVita Mojave Sage Dialysis, Victorville

80230-7200

Colorado Kidney Care, Denver

01107-1369

Renal and Transplant Associates of New England, PC, Springfield

55404-1212

DaVita Clinical Research, Minneapolis

89129-6201

DaVita Pelican Point Dialysis, Las Vegas

87301-5655

High Desert Nephrology, Gallup

44302-1715

Akron Nephrology Associates, Inc., Akron

37404-2743

Southeast Renal Research Institute, Chattanooga

75057-6039

North Texas Kidney Disease Association, Lewisville

78229-3809

San Antonio Kidney Disease Center Physicians Group (Wurzbach Road), San Antonio

78251-1230

South Texas Renal Care Group (Westover Hills), San Antonio

78258-4800

San Antonio Kidney Disease Center Physicians Group (Carnoustie Drive), San Antonio

Sponsors
All Listed Sponsors
lead

Goldfinch Bio, Inc.

INDUSTRY